Industrial Strength Bio Past Seminars
2008 Tuesday, March 11, 2008
Pradip Mukerji, PhD
Vice President Strategic Expansion
Abbott Nutritionals "Effective Biotech Marketing" Tuesday, March 4
11:00 AM - 12:00 PM
Building 517, Lecture Hall Dr. Ann C. Miller
Commercialization Consulting Abstract: Dr. Miller will address the importance of aligning the biotech marketing strategy and messages across the three key constituents - the physicians, the patients and payers. All of these customers are critical to success. She will use a case study which includes physician and direct-to consumer communications to demonstrate the value of this alignment in creating effective biotech marketing. Bio: Dr. Ann Miller has spent over 20 years in biopharma marketing with experience across multiple therapeutic areas. Over the years she has had responsibility for all phases of the product lifecycle, including managing highly competitive, in-line brands; developing global and US launch plans; and preparing commercialization plans for Phase 2 and Phase 3 products. Dr. Miller started her career at Merck and Co., with jobs of increasing responsibility across multiple functions culminating in senior marketing roles. From 1995 to 1998, Dr. Miller was responsible for the US brand marketing of Merck's cholesterol lowering product and then ran the US FOSAMAX® osteoperosis francis for 3 years. In 2002, she moved to Amgen to help build the Global Marketing function with responsibility for the oncology franchise and subsequently, the anemia/nephrology franchise. She played a vital role in establishing Amgen's approach to marketing strategy development, known as Systematic Commercial Analysis, and global payer planning. In early 2006, she took over the responsibility for US osteoporosis launch of Denosumab®, Amgen's key pipeline product. Dr. Miller is currently doing commercialization consulting for a start-up company in Colorado. "Formulation Development of Protein Drugs"
Tuesday, February 26
11:00 AM - 12:00 PM
Building 517, Lecture Hall Dr. Steven Shire, Ph.D. Staff Scientist and Group Leader, Genentech Inc. Abstract: The effort to create a successful pharmaceutical requires development of a formulation that meets several criteria. Clearly stability is an important goal in such a development but several other requirements need to be met in order to have a successful formulation. Issues that need to be addressed include scale up manufacturing process for the formulation, compatibility with the delivery route, use of acceptable excipients, and value added to a commercial product. This presentation will focus on the challenges to create a sufficiently stable formulation that can be manufactured and will be compatible with the administration route. Complications such as the use of delivery devices or requirement to formulate for sustained delivery will also be discussed. Bio: Dr. Shire received his Ph.D. from Indiana University Chemistry Department and, after Post Doctoral Training at the University of Connecticut, bgan his career at Genentech as Research Scientist in the Department of Protein Chemistry. He was involved in the early work to isolate heterologous recombinant proteins expressed in bacterial systems. Shortly after the creation of the Pharmaceutical Research and Development Department at Genetech, he joined the department where he made numerous contributions to development of protein formulation and delivery. Currently he is a Staff Scientist and Group Leader in the Late Stage Pharmaceutical Pharmacy. He has published over 50 reviews and papers dealing wtih various aspects of formulation and pharmaceutical development of therapeutic proteins. 2007 "Careers in the Life Science Industry: A View from the Desk"
Note: Introduction, approximately 6 minutes
Dr. Jerald Feitelson, Ph.D, Business Development, IP & Alliance Management, Beckman Coulter
Introduced by Animesh Ray Tuesday, November 27, 2007
Medical Device Entrepreneurship:
Confessions of a Repeat Offender
Tom Berryman, President & CEO, Wavetec Vision Systems Inc.
Introduced by Gail Baura Tuesday, November 6, 2007
Mark Reynolds, Gen-Probe Inc.
Introduced by Jim Sterling Tuesday, October 30, 2007
Jay Hagen, President, Amgen Ventures
Introduced by Steve Casper Tuesday, October 23, 2007
Joseph H. Schulman, PhD, President & Chief Scientist, Alfred E. Mann Foundation for Biomedical Research
Introduced by Molly Schmid October 2, 2007
Carol Mitchell, MD, Eli Lilly October 24, 2006
Dr. Joey M. Studts
Principal Scientist, Boehringer Ingelheim
Eukaryotic Cells Ride the Wave: Expanding the Drug Discovery Pipeline by Improving Protein Production Technology (2.5 MB)
|
